BioAge Labs (BIOA) EBITDA Margin (2025 - 2026)
BioAge Labs' (BIOA) quarterly EBITDA Margin came in at 1196.78% in Q2 2026, down 16979.0% year-over-year from N/an in Q2 2025, and down 30.74% quarter-over-quarter from 915.4% in Q1 2026.
Powered by 
Analysis
BioAge Labs (BIOA) EBITDA Margin (2025 - 2026) Analysis & Trends
BioAge Labs has disclosed EBITDA Margin across 2 years of filings, most recently posting 1196.78% for Q2 2026.
- In Q2 2026, EBITDA Margin fell 16979.0% year-over-year to 1196.78%; the TTM figure through Jun 2026 stood at 1026.28% (up 133792.0% YoY), while the FY2025 annual figure was 1031.46%, changed N/A from the prior year.
- EBITDA Margin came in at 1196.78% for Q2 2026 at BioAge Labs, down from 915.4% in the prior quarter.
- In the past five years, EBITDA Margin ranged from a high of 915.4% in Q1 2026 to a low of 1196.78% in Q2 2026.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 211.73 Bn | 197.74 Bn | 7.24 Bn | 34.95% |
| 2 | Gilead Sciences | 180.92 Bn | 177.74 Bn | 6.22 Bn | -133.21% |
| 3 | Vertex Pharmaceuticals | 132.16 Bn | 124.30 Bn | 2.84 Bn | 37.40% |
| 4 | Regeneron Pharmaceuticals | 82.89 Bn | 74.90 Bn | 3.93 Bn | 30.15% |
| 5 | Argenx Se | 61.41 Bn | 56.23 Bn | 1.37 Bn | 32.54% |
| 6 | Moderna | 53.99 Bn | 48.85 Bn | 52.00 Mn | -562.07% |
| 7 | Alnylam Pharmaceuticals | 34.48 Bn | 31.18 Bn | 992.69 Mn | 17.93% |
| 8 | Biogen | 31.15 Bn | 29.86 Bn | 1.96 Bn | -23.56% |
| 9 | Roivant Sciences | 30.05 Bn | 30.05 Bn | 1.16 Mn | -25,380.93% |
| 10 | BioAge Labs | 409.83 Mn | 409.83 Mn | -14.23 Mn | -1,196.78% |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -1,196.78% |
| Mar 31, 2026 | -915.40% |
| Dec 31, 2025 | -923.42% |
| Sep 30, 2025 | -1,126.58% |
| Jun 30, 2025 | -1,026.99% |
| Mar 31, 2025 | -1,133.43% |